Antifungal prophylaxis for solid organ transplant recipients: Seeking clarity amidst controversy

Clinical Infectious Diseases

Volumn 31, Issue 2, 2000, Pages 545-553

  Singh, N ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CORTICOSTEROID; CYCLOSPORIN; FLUCONAZOLE; ITRACONAZOLE; NYSTATIN; OKT 3; SIMVASTATIN; TACROLIMUS;

ARTICLE; ASPERGILLUS; CANDIDA; CLINICAL TRIAL; DRUG EFFICACY; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MYCOSIS; NEPHROTOXICITY; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; HUMANS; MYCOSES; ORGAN TRANSPLANTATION;

EID: 0034458471     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313943     Document Type: Article

References (84)

1. Fungal infections in lung and heart-lung transplant recipients: Report of 9 cases and review of the literature
2. Invasive aspergillosis in transplant recipients
3. Risk factors for invasive fungal infections complicating orthotopic liver transplantation
4. Risk factors for development of infectious complications in adult liver transplant recipients receiving tacrolimus (FK506) immunosuppression
5. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients
6. Invasive fungal infections in liver transplant recipients receiving tacrolimus as a primary immunosuppressive agent
7. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients
8. Aspergillus airway colonization and invasive disease after lung transplantation
9. Aspergillus and lung transplantation
10. Aspergillus infection in single and double lung transplant recipients
11. Saprophytic fungal infections and lung transplantation - Revisited
12. Infectious complications following pancreatic transplantation: Incidence, microbiological and clinical characteristics, and outcome
13. Intra-abdominal fungal infections after pancreatic transplantation: Incidence, treatment, and outcome
14. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids
15. Fungal infections following heart transplantation
16. Infections in heart transplant recipients: The experience of the Italian heart transplantation program
17. Ganciclovir/acyclovir and fluconazole prophylaxis after simultaneous kidney-pancreas transplantation
18. Prospective study of renal transplant infections in 50 consecutive patients
19. Infection in renal transplant recipients
20. Influence of rejection therapy on fungal and nocardial infections in renal transplant recipients
21. Incidence and significance of Aspergillus cultures following liver and kidney transplantation
22. Fungal infection following renal transplantation
23. Aspergilosis pulmonar invasiva en el trasplante renal y renopancreatico
24. Aspergillosis in 25 renal transplant patients
25. Infectious complications after small bowel transplantation in adults: An update
26. Fungal infection and liposomal amphotericin B (AmBisome) therapy in liver transplantation: A 2-year review
27. Invasive aspergillosis in liver transplant recipients in the 1990s
28. Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression
29. Risk factors for systemic fungal infections in liver transplant recipients
30. Central nervous system lesions in liver transplant recipients: Prospective assessment of indications for biopsy and implications for management
31. Thrombocytopenia in liver transplant recipients: Predictors, impact on fungal infections, and role of endogenous thrombopoietin
32. Systemic fungal infections following orthotopic liver transplantation for acute liver disease
33. Human herpesvirus-6 in liver transplant recipients: Role in pathogenesis of fungal infections, neurologic complications, and impact on outcome
34. Ten-year review of invasive aspergillosis detected at necropsy
35. Characterization and impact of wound infection after pancreas transplantation
36. Invasive aspergillosis in renal transplant recipients: Correlation with corticosteroid therapy
37. Fungal infections in solid-organ transplantation
38. Risk factors for deep Candida infections in liver transplant recipients
39. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients
40. Development and validation of a prediction rule for invasive fungal infection in liver transplant recipients
41. Infectious complications in heart-lung transplantation, analysis of 200 episodes
42. Airway stenoses after lung transplantation: Management with expanding metal stents
43. Preemptive therapy with azoles in lung transplant patients
44. Ulcerative tracheobronchitis after lung transplantation: A new form of invasive aspergillosis
45. Infectious complications of lung transplantation
46. Bronchocentric mycosis occurring in transplant recipients
47. Prospective study of transbronchial biopsies in the management of heart-lung and single-lung transplant patients
48. Simultaneous pancreas-kidney versus kidney-alone transplants in diabetics: Increased risk of early cardiac death and acute rejection following pancreas transplants
49. Pneumonia after heart transplantation: A multi-institutional study
50. Respiratory complications of cardiac transplantation
51. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses
52. Efficacy of itraconazole prophylaxis against systemic fungal infection in liver transplant recipients
53. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trail
54. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis
55. Amphotericin B colloidal dispersion versus amphotericin B as therapy for invasive aspergillosis
56. Liposomal amphotericin B and amphotericin B-deoxycholate show different immunoregulatory effects on human peripheral blood mononuclear cells
57. Efficacy and safety of AmBisome and Abelcet in transplant patients: A multicenter study
58. Lipid-based amphotericin B for treatment of fungal infections
59. An EORTC international multicenter randomized trial (EORTC number 19923) comparing 2 dosages of liposomal amphotericin B for treatment of invasive aspergillosis
60. Fungal infection prophylaxis in high-risk liver transplant recipients
61. Systemic mycoses during prophylactic use of liposomal amphotericin B (AmBisome) after liver transplantation
62. Markers of coccidioidomycosis before cardiac or renal transplantation and the risk of recurrent infection
63. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis
64. New methods of delivery of amphotericin B
65. Combination therapy in a rat model of pulmonary aspergillosis
66. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis
67. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis
68. Significant reduction in the number of fungal infections after lung, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis
69. Treatment of Aspergillus-related ulcerative tracheobronchitis in lung transplant
70. Analysis of antifungal prophylaxis in lung transplantation
71. Nebulized amphotericin B lipid complex prophylaxis is associated with a low rate of invasive fungal infections after lung transplantation
72. Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis
73. Antifungal prophylaxis during the early postoperative period of lung transplantation
74. Antifungal prophylaxis with itraconazole in neutropenic patients: Pharmacological, microbiological and clinical aspects
75. Invasive aspergillosis in transplant recipients. A large multicentric study
76. Rhabdomyolysis after lung transplantation
77. Randomized trial of fluconazole versus nystatin for prophylaxis of candida infection after liver transplantation
78. Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial
79. Economic evaluation of fluconazole versus nystatin prophylaxis in liver transplant recipients
80. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients
81. Fluconazole prophylaxis for high-risk liver transplant recipients
82. Efficacy of itraconazole prophylaxis for aspergillosis in lung transplant recipients
83. Definitions of EORTC-IFICG group